Amgen’s Blincyto approved by FDA for new acute lymphoblastic leukaemia indication

Amgen’s Blincyto (blinatumomab) has been granted approval by the US Food and Drug Administration (FDA) to treat adult and paediatric patients aged one month and older with an aggressive type of blood cancer.